Form 4: Neurogene Inc. Insider Sells Shares Under 10b5-1 Plan

Neurogene Inc. President and CFO Christine Mikail Cvijic has sold a significant number of company shares through a pre-arranged trading plan.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc., reported the sale of company stock on July 1st and 2nd, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on August 18, 2025.
• A total of 739 shares were sold on July 1, 2026, at a weighted average price of $34.059.
• On July 2, 2026, an additional 2,531 shares were sold at a weighted average price of $34.579, and 1,530 shares were sold at a weighted average price of $35.227.
• Following these sales, Cvijic beneficially owns 88,840 shares of common stock.
• The reported sales include shares held jointly with her spouse, David Cvijic.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be a negative signal, the execution of a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.

Negatives

• Insider selling activity can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established 10b5-1 plan, which is designed to mitigate concerns about insider trading.

Risks

• The filing does not explicitly mention any new risks. However, any significant insider selling, even under a 10b5-1 plan, could be interpreted by the market as a signal of reduced confidence by management, potentially impacting share price.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025.
• Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
• The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence in the biotechnology sector as executives manage personal finances. The key is to monitor the volume and frequency of such sales in conjunction with company performance and clinical trial updates.

Related Party Transactions

• Shares sold were held jointly by the reporting person (Christine Mikail Cvijic) and her spouse, David Cvijic.

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a 10b5-1 plan, as a potential negative signal, though the plan's existence provides some reassurance.
• Employees: Similar to shareholders, may view insider sales with caution.
• Management: The reporting person is a key executive (President and CFO), and their sales could influence market perception.

Next Steps

• Continue to monitor future Form 4 filings for any additional insider transactions.
• Observe the company's performance and any public announcements for context regarding insider trading activity.

Key Dates

Keywords

Neurogene Inc., NGNE, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Christine Mikail Cvijic, President and CFO, Beneficial Ownership